Merck appoints new CFO; Copaxone generic succeeds in trial; Lupin enters Mexican eye-drug market;

@FiercePharma: Colorado vaccine bill: Necessary education or treating parents like 'idiots'? - Fierce Vaccines. Story | Follow @FiercePharma

@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. More | Follow @TracyStaton

@EricPFierce: FDA 's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. News | Follow @EricPFierce

@CarlyHFierce: ICYMI, here's that link again to yesterday's full issue of FiercePharmaMarketing. It includes a walking bladder. More | Follow @CarlyHFierce

> Merck ($MRK) has appointed Robert Davis to succeed Peter Kellogg as CFO. Release

> Dutch drug developer Synthon reports that its generic of Teva's ($TEVA) multiple sclerosis treatment Copaxone matched the original's safety and efficacy in a Phase III trial. More

> Mylan ($MYL) has won a breach of contract lawsuit against GlaxoSmithKline ($GSK) along with $106.7 million in damages. Release

> Bristol-Myers Squibb ($BMY) and Pfizer ($PFE) said their blood thinner Eliquis beat warfarin at reducing the risk of stroke, regardless of whether patients' blood pressure was under control. Release

> Merck KGaA will propose a 2-for-1 stock split to shareholders at the company's annual meeting in May. Report

> India's Lupin has picked up Mexican eye-drug maker Laboratorios Grin for an undisclosed amount. More

> A large group of researchers is asking JAMA to retract a November study linking testosterone treatments with cardiovascular risks. More

Medical Device News

@FierceMedDev: Baxter will keep its sprawling medical products arm and spin off its biopharmaceuticals into a separate company. More | Follow @FierceMedDev

@MarkHFierce: Zyomyx grabs some funding to launch its HIV/AIDS test in emering markets. More via FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. Article via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Supercomputer from "Jeopardy" game show will help scientists read mutations, find drug cocktail for cancer. Story via New York Times | Follow @EmilyWFierce

> J&J's Ethicon division settles a vaginal mesh case for $11M. More

> Crucial EU compact vote on U.S.-style device approval system raises industry concern. Story

Biotech News

@FierceBiotech: ICYMI: GlaxoSmithKline joins a biotech brain trust to make R&D more efficient. News | Follow @FierceBiotech

@JohnCFierce: I'll be curious to see how Novartis does with the early application on 'breakthrough' drug. Looks promising. Story | Follow @JohnCFierce

@DamianFierce: Brief on $BAX's breakup: creates a $6B biopharma player with focus on bleeding disorders, immune deficiencies. More | Follow @DamianFierce

@EmilyMFierce: Antioxidant could slow progression of Lou Gehrig's disease, extend lifespan. News | Follow @EmilyMFierce

> Exelixis' shares flogged after lead drug disappoints at interim PhIII point. More

> RuiYi banks $15M from A-list backers to amp up Chinese R&D. Article

Pharma Manufacturing News

> Baxter, FDA scramble to overcome shortage of nitroglycerin. News

> GSK says someone tampered with alli bottles. News

> FDA takes aim at yet another Indian API maker. Story

> Market force may put quality at forefront of all generics makers. Article

> FDA's Woodcock throws cold water on generic drug research. Story

> French CMO Novacep sees growth. Brief

Vaccines News

> 'Breakthrough' nod for Pfizer MenB candidate sets up showdown with Bexsero. Story

> PhIII fail further dents hopes for GSK's cancer vaccine. Story

> Colorado vaccine bill: Necessary education or treating parents like 'idiots'? Article

> Novartis' Bexsero wins U.K. recommendation in government U-turn. News

> Government H5N1 vaccine orders drive jump in sales at Sinovac. Story

> Buzz: Baxter is considering selling its vaccine unit. Brief

And Finally... Generation X-ers are fatter and twice as likely to have diabetes as Baby Boomers were at the same age. Report

 

 

Suggested Articles

In a high-stakes patent lawsuit between the CAR-T companies of Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.

Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.